Vagus Nerve Stimulation (VNS)

Similar documents
Intrathecal Opioid Therapy for Management of Chronic Pain

Continuous Glucose Monitoring (CGM)

Transcranial Magnetic Stimulation

Pulmonary Rehabilitation

Herniated Disc Treatment Non-covered Procedures

Anesthesia for Routine Gastrointestinal Endoscopic Procedures (Additional description)

Continuous Glucose Monitoring (CGM)

Velcade (bortezomib) Document Number: IC-0137

Clinical Policy: Vagus Nerve Stimulation Reference Number: PA.CP.MP.12

MEDICAL POLICY SUBJECT: VAGUS NERVE STIMULATION

Krystexxa (pegloticase) Document Number: IC-0158

All Indiana Health Coverage Programs Hospitals, Ambulatory Surgical Centers, Physicians, and Durable Medical Equipment Providers

Intravitreal Avastin (Bevacizumab)

Eylea (aflibercept) Document Number: IC-0026

Imfinzi (durvalumab) (Intravenous)

High Frequency Chest Wall Oscillating Devices (HFCWO) (Airway Clearance Systems)

POLICIES AND PROCEDURE MANUAL

Dates Reviewed: 12/2012, 3/2013, 6/2013, 9/2013, 11/2013, 12/2013, 3/2014, 6/2014, 9/2014, 12/2014,

Document Number: IC I. Length of Authorization. Dosing Limits

Tecentriq (atezolizumab) (Intravenous)

Corporate Medical Policy

Cyramza (ramucirumab) (Intravenous)

HF10 THERAPY 2018 Ambulatory Surgery Center Reimbursement and Coding Reference Guide

Rituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous)

See Policy CPT/HCPCS CODE section below for any prior authorization requirements

Reduction Mammoplasty

Cardiac Disease Screening Lipid Profile

Treatment or Removal of Benign Skin Lesions

Subject: Gastrointestinal Electrical Stimulation (GES) and Vagus Nerve Blocking Therapy (VBLOC) for Obesity. Original Effective Date: 7/8/2015

H F 1 0 T H E R A P Y R E I M B U R S E M E N T R E F E R E N C E G U I D E

Trelstar (triptorelin) (Intramuscular)

Clinical Policy: Vagus Nerve Stimulation

Surgical Treatment for Achalasia

Kyphoplasty and Vertebroplasty

Cardiac Disease Screening Lipid Profile

Cortical Stimulation for Epilepsy (NeuroPace )

Colony Stimulating Factors: Zarxio (filgrastim sndz) (Subcutaneous/Intravenous)

Yervoy (ipilmumab) Last Review Date: 03/25/2014 Date of Origin: 11/28/2011. Prior Auth Available: Post-Service Edit:

2 016 HF10 THERAPY HOSPITAL OUTPATIENT DEPARTMENT AND AMBULATORY SURGERY CENTER REIMBURSEMENT REFERENCE GUIDE

Ilaris (canakinumab) (Subcutaneous)

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Review Criteria Implantable Neurostimulators

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association

Nevro Reimbursement Support

Occipital Nerve Stimulation Corporate Medical Policy

2016 HF10 THERAPY REIMBURSEMENT REFERENCE GUIDE

Colony Stimulating Factors: Nivestym (filgrastim-aafi) (Subcutaneous/Intravenous)

Specialised Services Policy: CP23 Vagal Nerve Stimulation

Chapter 4 Section 20.1

Chapter 4 Section 20.1

Trelstar Depot (triptorelin)

Chapter 4 Section 20.1

Erythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) (Subcutaneous/Intravenous) *NON DIALYSIS* Document Number: IC 0242

Clinical Commissioning Policy: Vagal Nerve Stimulation (VNS) December Reference : NHSCB/D4/c/7

Inspire Medical Systems. Physician Billing Guide

Clinical Policy Title: Vagus nerve stimulation

Clinical Policy: Gastric Electrical Stimulation Reference Number: CP.MP.40

Spinal Cord Stimulators

Understand the New 2019 Neurostimulator Analysis-Programming CPT Coding Structure and Associated Relative Value Units

Clinical Policy: Digital EEG Spike Analysis

Inspire Medical Systems. Hospital Billing Guide

21 ST CENTURY TECHNOLOGY IN PEDIATRIC NEUROLOGIC DISORDERS PEDIATRIC NEUROLOGIC DISORDERS YOUR LEARNING EXPERIENCE LEARNING OBJECTIVES

Vagus Nerve Stimulation (VNS)

Alimta (pemetrexed) Document Number: IC 0007

Knee Cartilage Transplants

Introducing Vagus Nerve Stimulation for Epilepsy

Vagus Nerve Stimulation

Neuromodulation in Dravet Syndrome. Eric BJ Segal, MD Director of Pediatric Epilepsy Northeast Regional Epilepsy Group Hackensack, New Jersey

Clinical Commissioning Policy: Deep Brain Stimulation for Refractory Epilepsy (all ages) NHS England Reference: P

1. POLICY: Magnetic Resonance Image Guided High Intensity Focused Ultrasound (MRgFUS) for Essential Tremor

NEMOS. t-vns for treatment of drug-resistant epilepsy

Cigna Medical Coverage Policy

Seventy percent of patients with epilepsy can be

DEEP BRAIN STIMULATION

Prolia /Xgeva (denosumab) Document Number: IC-0098

Deep Brain Stimulation (DBS)

Clinical Policy: Gastric Electrical Stimulation

Coverage Summary. Wound Treatments

MP.094.MH Transcutaneous Electrical Nerve Stimulators

Clinical Policy Title: Vagus nerve stimulation

Sympathetic Electrical Stimulation Therapy for Chronic Pain

Breast Reconstruction Surgery after Mastectomy or Lumpectomy

Denominator Exceptions

Negative Pressure Wound Therapy (NPWT) (Vacuum-Assisted Wound Closure)

The Role of a Vascular Surgeon in the Treatment of Drug Resistant Epilepsy

Epilepsy 101. Overview of Treatment Georgette Smith, PhD, APRN, CPNP. American Epilepsy Society

Gastric Electrical Stimulation Corporate Medical Policy

Neurostimulator Devices and Supplies

Percutaneous Electrical Nerve Stimulation (PENS) and Percutaneous Neuromodulation Therapy (PNT)

PACEMAKERS ARE NOT JUST FOR THE HEART! Ab Siadati MD

Inspire Medical Systems. Hospital Billing Guide

Highmark Medical Policy Bulletin

Cardiac Rhythm Management Coder 2017

Contractor Number 03201

Medical Policy. Description/Scope. Position Statement. Rationale

TEXAS - MAC - PART B - TRAILBLAZER RADIOLOGY TABLE OF CONTENTS

POLICIES AND PROCEDURE MANUAL

All patients with a diagnosis of treatment resistant (intractable) epilepsy.* Denominator Statement

MEDICAL POLICY SUBJECT: GASTRIC ELECTRICAL STIMULATION

Transcription:

Vagus Nerve Stimulation (VNS) Date of Origin: 12/2008 Last Review Date: 06/27/2018 Effective Date: 07/01/2018 Dates Reviewed: 07/2010, 07/2011, 07/2012, 05/2013, 07/2014, 01/2016, 01/2017, 06/2018 Developed By: Medical Necessity Criteria Committee I. Description A vagus nerve stimulator (VNS) is an implantable device that is used as an adjunctive treatment for medical refractory partial onset seizures as well as for the treatment of severe or chronic depression. Similar to a pacemaker, the VNS pulse generator is surgically implanted under the skin near the collar bone. A lead wire connects the pulse generator to the left vagus nerve in the neck. The VNS is then programmed to produce weak electrical signals that travel along the vagus nerve to the brain at regular intervals. These signals help prevent the electrical bursts in the brain that cause seizures. The signals can also affect mood centers of the brain, possibly improving depressive symptoms> II. Criteria (CWQI: HCS-0068A) A. Moda Health will cover vagus nerve stimulators to plan limitations when ALL of the following criteria are met a. The member is 4 years of age or older; b. The member has medically refractory partial onset seizures and 1 or more of the following: i. Medically refractory seizures that occur in spite of therapeutic levels of antiepileptic medications; or ii. Seizures that cannot be treated with therapeutic levels of anti-epileptic drugs because of intolerable side effects c. Unsuccessful surgical invention (lesionectomy or medial temporal lobectomy) with 1 or more of the following conditions: i. Seizures refractory to surgical intervention ii. Patient was not a surgical candidate iii. Patient refused surgical intervention B. Moda Health considers vagus nerve stimulation experimental and investigational for use in treatment-resistant depression due to the lack of well-designed controlled clinical trials. Only one randomized control trial evaluating the effectiveness of VNS for treatment-resistant depression has been identified. This study did not find statistically significant improvement on most measures of depression. Therefore, the available evidence is not sufficient to permit conclusions on the effect of VNS therapy on health outcomes or it effects compared with alternative therapies for depression treatment. C. Moda Health considers vagus nerve stimulation experimental and investigational for the treatment of all other indications, including but not limited to, depression, cognitive impairment associated Moda Health Plan Vagus Nerve Stimulator Page 1/7

with Alzheimer s disease, anxiety disorders, autism, obesity, headaches, addictions, Tourette s syndrome and obsessive compulsive disorder. The effectiveness of vagus nerve stimulation for the treatment of these, or other conditions, has not been established. III. Information Submitted with the Prior Authorization Request: 1. Medical records from the treating neurologist documenting a diagnosis of partial onset seizures as well as medical and surgical treatment tried and failed. IV. Applicable CPT or HCPC codes Codes Description 61885 Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array 61886 Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to two or more electrode array 64553 Percutaneous implantation of neurostimulator electrodes; cranial nerve 64573 Incision for implantation of neurostimulator electrodes; cranial nerve 64568 Incision for implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator 64569 Revision or replacement of cranial nerve (eg, vagus nerve) neurostimulator electrode array, including connection to existing pulse generator 64570 Removal of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator L8680 Implantable neurostimulator electrode, each L8681 Patient programmer (external) for use with implantable programmable neurostimulator pulse generator L8682 Implantable neurostimulator radiofrequency receive L8683 Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receive L8685 Implantable neurostimulator pulse generator, single array, rechargeable, includes extension L8686 Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension L8687 Implantable neurostimulator pulse generator, dual array, rechargeable, includes Extension L8688 Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension Moda Health Plan Vagus Nerve Stimulation Page 2/7

V. References 1. Amar AP, DeGiorgio CM, Tarver WB, et al. Long-term multicenter experience with vagus nerve stimulation for intractable partial seizures: results of the XE5 trial. Stereotact Funct Neurosurg. 1999;73(1-4):104-8. 2. American Psychiatric Association: Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000;157:1-45. 3. Ansari S, Chaudhri K, Al Moutaery KA. Vagus nerve stimulation: Indications and limitations. Acta Neurochir Suppl. 2007;97(Pt 2):281-286. 4. Ardesch JJ, Buschman HPJ, Wagner-Schimmel LJJC, van der Aa HE, Hageman G. Vagus nerve stimulation for medically refractory epilepsy: A long-term follow-up study. Seizure. 2007 Oct;16(7):579-85. 5. Balabanov A, Rossi MA. Epilepsy surgery and vagal nerve stimulation: what all neurologists should know. Semin Neurol. 2008 Jul;28(3):355-63. Epub 2008 Jul 24. 6. Beekwilder JP, Beems T. Overview of the clinical applications of vagus nerve stimulation. J Clin Neurophysiol. 2010;27(2):130-138. 7. Camilleri M, Toouli J, Herrera MF, et al. Intra-abdominal vagal blocking (VBLOC therapy): Clinical results with a new implantable medical device. Surgery. 2008;143(6):723-731. 8. Centers for Medicare and Medicaid Services (CMS). National Coverage Determination: Vagus nerve stimulation for resistant depression. New/Revised NCD #160.18. Accessed May 22, 2013 at: http://www.cms.gov/medicare-coverage-database/details/ncddetails.aspx?ncdid=230&ncdver=2&docid=160.18&kq=true&bc=gaaaaagaaaaaaa%3d%3d& 9. De Herdt V, Boon P, Ceulemans B, Hauman H, Lagae L, Legros B, et al. Vagus nerve stimulation for refractory epilepsy: A Belgian multicenter study. Eur J Paediatr Neurol. 2007 Sep;11(5):261-9. 10. DeGiorgio, C, Heck C, Bunch S; J. Britton J, Green P, Lancman M, et al. Vagus nerve stimulation for epilepsy: Randomized comparison of three stimulation paradigms. Neurology 2005;65:317-9. 11. Dietrich S, Smith J, Scherzinger C, et al. A novel transcutaneous vagus nerve stimulation leads to brainstem and cerebral activations measured by functional MRI. Biomed Tech (Berl). 2008;53(3):104-111. 12. Fochtmann LJ, Gelenberg AJ. Guideline Watch: Practice guideline for the treatment of patients with major depressive disorder, 2 nd Edition.. 13. George MS, Nahas Z, Borckardt JJ, et al. Vagus nerve stimulation for the treatment of depression and other neuropsychiatric disorders. Expert Rev Neurother. 2007;7(1):63-74. 14. George MS, Sackeim HA, Rush J, et al. Vagus nerve stimulation: a new tool for brain research and therapy. Society of Biol. Psych. 2000;47:287-295. 15. Institute for Clinical Systems Improvement (ICSI). Major depression in adults in primary care. ICSI Health Care Guideline. 10th e d. Bloomington, MN: ICSI; May 2007. 16. Lund C, Kostov H, Blomskjøld B, Nakken KO. Efficacy and tolerability of long-term treatment with vagus nerve stimulation in adolescents and adults with refractory epilepsy and learning disabilities. Seizure. 2011;20(1):34-37. 17. National Institute for Clinical Excellence (NICE). Vagus nerve stimulation for refractory epilepsy in children. March 16, 2004. Accessed August 16, 2010. Available at URL address: http://www.nice.org.uk/guidance/index.jsp?action=download&o=30908 Moda Health Plan Vagus Nerve Stimulation Page 3/7

18. Renfroe JB, Wheless JW. Earlier use of adjunctive vagus nerve stimulation therapy for refractory epilepsy. Neurology. 2002 Sep 24;59(6 Suppl 4):S26-30. 19. Rielo D, Benbadis S. Vagus nerve stimulation. emedicine. February 14, 2007. Accessed on May 22, 2013 available at: http://www.emedicine.com/neuro/topic559.htm. Accessed December 4, 2008. 20. Trescher WH, Lesser RP. The Epilepsies. Vagus Nerve Stimulation. Bradley: Neurology in Clinical Practice. 5th ed. Butterworth Heinemann Elsevier Philadelphia, PA. 2008. Ch 71. 51. U.S. Food and Drug Administration (FDA). New Device Approval VNS Therapy S 21. U.S. Food and Drug Administration (FDA). Summary of Safety and Effectiveness Data. Accessed on May 22, 2013 at: http://www.fda.gov/medicaldevices/productsandmedicalprocedures/deviceapprovalsandclear ances/recently-approveddevices/ucm078532.htm. 22. Wheless JW, Baumgartner J. Vagus nerve stimulation therapy. Drugs Today. 2004 Jun;40(6):501-15. 23. Physician Advisors VI. Annual Review History Review Date Revisions Effective Date 05/2013 Annual Review: Added table with review date, revisions, 05/2013 and effective date. 07/2014 Annual Review: No change 07/2014 01/2016 Annual Review: No change 01/27/2016 01/2017 Annual Review: Updated to new template, removed word 01/25/2017 refractory from the depression indication in III.C 06/2018 Annual Review: No change 6/27/2018 Appendix 1 Covered Diagnosis Codes ICD-10 G40.A01 G40.A09 G40.A11 G40.A19 ICD-10 Description Absence epileptic syndrome, not intractable, with status Absence epileptic syndrome, not intractable, without status Absence epileptic syndrome, intractable, with status Absence epileptic syndrome, intractable, without status G40.101 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, with status G40.109 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, without status Moda Health Plan Vagus Nerve Stimulation Page 4/7

ICD-10 ICD-10 Description G40.111 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, with status G40.119 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, without status G40.201 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, with status G40.209 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, without status G40.211 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, with status G40.219 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, without status G40.301 Generalized idiopathic epilepsy and epileptic syndromes, not intractable, with status G40.309 Generalized idiopathic epilepsy and epileptic syndromes, not intractable, without status G40.311 Generalized idiopathic epilepsy and epileptic syndromes, intractable, with status G40.401 Other generalized epilepsy and epileptic syndromes, not intractable, with status G40.409 Other generalized epilepsy and epileptic syndromes, not intractable, without status G40.411 Other generalized epilepsy and epileptic syndromes, intractable, with status G40.419 Other generalized epilepsy and epileptic syndromes, intractable, without status G40.501 Epileptic seizures related to external causes, not intractable, with status Moda Health Plan Vagus Nerve Stimulation Page 5/7

ICD-10 ICD-10 Description G40.509 Epileptic seizures related to external causes, not intractable, without status G40.802 Other epilepsy, not intractable, without status G40.804 Other epilepsy, intractable, without status G40.821 Epileptic spasms, not intractable, with status G40.822 Epileptic spasms, not intractable, without status G40.823 Epileptic spasms, intractable, with status G40.824 Epileptic spasms, intractable, without status G40.901 Epilepsy, unspecified, not intractable, with status G40.909 Epilepsy, unspecified, not intractable, without status G40.911 Epilepsy, unspecified, intractable, with status G40.919 Epilepsy, unspecified, intractable, without status O99.351 Diseases of the nervous system complicating pregnancy, first trimester O99.352 Diseases of the nervous system complicating pregnancy, second trimester O99.353 Diseases of the nervous system complicating pregnancy, third trimester O99.355 Diseases of the nervous system complicating the puerperium R56.01 Complex febrile convulsions R56.1 Post traumatic seizures R56.9 Unspecified convulsions Appendix 2 Centers for Medicare and Medicaid Services (CMS) Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, 50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx. Additional indications may be covered at the discretion of the health plan. Moda Health Plan Vagus Nerve Stimulation Page 6/7

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD): NCD/LCD Document (s): NCD 160.18 https://www.cms.gov/medicare-coverage-database/details/ncddetails.aspx?ncdid=230&ncdver=2&coverageselection=both&articletype=all&policytype=final&s=oregon& KeyWord=Vagus+Nerve+Stimulation&KeyWordLookUp=Title&KeyWordSearchType=And&bc=gAAAACAAAAAA AA%3d%3d& Medicare Part B Administrative Contractor (MAC) Jurisdictions Jurisdiction Applicable State/US Territory Contractor F (2 & 3) AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ Noridian Healthcare Solutions, LLC Moda Health Plan Vagus Nerve Stimulation Page 7/7